(Q37976256)

26 August 2017

title

Epigenetic regulation in RCC: opportunities for therapeutic intervention? (English)

1 reference

26 August 2017

Marcus Vetter

3

0 references

Charles Swanton

object named as

Charles Swanton

series ordinal

5

0 references

Lisa Pickering

series ordinal

4

object named as

Lisa Pickering

1 reference

26 August 2017

James Larkin

1

1 reference

26 August 2017

Xin Yi Goh

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

17 January 2012

1 reference

26 August 2017

published in

Nature Reviews Urology

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

147-155

1 reference

26 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Global increases in kidney cancer incidence, 1973-1992.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Novel approaches in the therapy of metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Advanced insights into the biology of malignant lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

2004 WHO classification of the renal tumors of the adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Subclassification of renal cell neoplasms: an update for the practising pathologist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Role of VHL gene mutation in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Xp11 translocation renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Incidence, predictors and associated outcomes of renal cell carcinoma in long-term dialysis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Immunotherapy for advanced renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Metastatic renal cell carcinoma: many treatment options, one patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Magnesium-L-aspartate-HCl and magnesium-oxide: bioavailability in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Eukaryotic DNA methylation: facts and problems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Role of chromatin structure in the regulation of transcription by RNA polymerase II.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone acetylation in chromatin structure and transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Molecular biology. Chromatin higher order folding--wrapping up transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone lysine methylation: a signature for chromatin function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone acetylation and transcriptional regulatory mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone modifications and nuclear architecture: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Chromatin modifications and their function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Multivalent engagement of chromatin modifications by linked binding modules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Perceptions of epigenetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone methylation: dynamic or static?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The diverse functions of histone lysine methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone arginine methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Role of protein methylation in regulation of transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The complex language of chromatin regulation during transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Regulation of histone methylation by demethylimination and demethylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

MLL: a histone methyltransferase disrupted in leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Roles of the EZH2 histone methyltransferase in cancer epigenetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The polycomb group protein EZH2 is involved in progression of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Aberrations of EZH2 in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

High-resolution profiling of histone methylations in the human genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Deregulation of H3K27 methylation in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

G9a and Glp methylate lysine 373 in the tumor suppressor p53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The SWI/SNF complex and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Paradoxical relationship between chromosomal instability and survival outcome in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

SWI/SNF regulates the cellular response to hypoxia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Heterogeneity in renal cell carcinoma and its impact no prognosis--a flow cytometric study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Sunitinib rechallenge in metastatic renal cell carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Phase II open label study of valproic acid in spinal muscular atrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Epigenetic modifications as therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Clinical and molecular responses in lung cancer patients receiving Romidepsin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

HDAC inhibitors overcome first hurdle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.236

Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma

31 March 2020

1 reference

12 December 2020

Inactivation of BHD in sporadic renal tumors.

1 reference

12 December 2020

Different DNA ploidy patterns for the differentiation of common subtypes of renal tumors.

1 reference

12 December 2020

Histone modifications in cancer biology and prognosis

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced renal cell carcinoma.

1 reference

12 December 2020

Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells.

1 reference

12 December 2020

Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2011.236

1 reference

26 August 2017

1 reference